Trial Profile
Pharmacodynamic Effects of Vorapaxar as an Add-On Antiplatelet Therapy in Patients With and Without Diabetes Mellitus: The Optimizing Anti-Platelet Therapy In Diabetes MellitUS (OPTIMUS)-5 Study
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 12 May 2022
Price :
$35
*
At a glance
- Drugs Vorapaxar (Primary) ; Aspirin; Clopidogrel
- Indications Arterial thrombosis
- Focus Pharmacodynamics
- Acronyms OPTIMUS-5
- 05 Mar 2019 Status changed from active, no longer recruiting to completed.
- 27 Dec 2018 Status changed from recruiting to active, no longer recruiting.
- 27 Nov 2018 Planned End Date changed from 1 Dec 2018 to 1 Feb 2019.